Wnt/β-catenin pathway inhibitors, bone metabolism and vascular health in kidney transplant patients
Background and objectives Sclerostin, dickkopf-related protein 1 (DKK1), fibroblast growth factor-23 (FGF23) and α-klotho have been shown to play an important role in bone and vascular disease of chronic kidney disease. We aimed to evaluate the evolution of these bone markers in newly kidney transpl...
Gespeichert in:
| Veröffentlicht in: | Journal of nephrology 2023-05, Vol.36 (4), p.969-978 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 978 |
|---|---|
| container_issue | 4 |
| container_start_page | 969 |
| container_title | Journal of nephrology |
| container_volume | 36 |
| creator | Wang, Yue-Pei Sidibé, Aboubacar Fortier, Catherine Desjardins, Marie-Pier Ung, Roth-Visal Kremer, Richard Agharazii, Mohsen Mac-Way, Fabrice |
| description | Background and objectives
Sclerostin, dickkopf-related protein 1 (DKK1), fibroblast growth factor-23 (FGF23) and α-klotho have been shown to play an important role in bone and vascular disease of chronic kidney disease. We aimed to evaluate the evolution of these bone markers in newly kidney transplanted patients, and whether they are associated with bone metabolism and vascular stiffness.
Design, setting, participants and measurements
This is a longitudinal single-center observational cohort study. Circulating levels of Wnt/β-catenin pathway inhibitors (sclerostin, DKK1, FGF23 and α-klotho), arterial stiffness (carotid-femoral pulse-wave velocity (PWV), carotid-radial PWV, PWV ratio, augmented index) and bone parameters were assessed before (M0), and at 3 (M3) and 6 months (M6) after transplantation. Generalized estimating equations were conducted for comparative analyses between the three time points. We used a marginal structural model for repeated measures for the impact of changes in bone markers on the evolution of arterial stiffness. Multivariate linear regression analyses were performed for the associations between Wnt/β-catenin pathway inhibitors and mineral metabolism parameters.
Results
We included 79 patients (70% male; median age of 53 (44–60) years old). The levels of sclerostin (2.06 ± 1.18 ng/mL at M0 to 0.88 ± 0.29 ng/mL at M6,
p
≤ 0.001), DKK1 (364.0 ± 266.7 pg/mL at M0 to 246.7 ± 149.1 pg/mL at M6,
p
≤ 0.001), FGF23 (5595 ± 9603 RU/mL at M0 to 137 ± 215 RU/mL at M6,
p
≤ 0.001) and α-klotho (457.6 ± 148.6 pg/mL at M0 to 109.8 ± 120.7 pg/mL at M6,
p
|
| doi_str_mv | 10.1007/s40620-022-01563-y |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2771088873</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2771088873</sourcerecordid><originalsourceid>FETCH-LOGICAL-c347t-49f7a82f46822589a667592189624a8c2cded740b4aba5d77e061fbe2eb166303</originalsourceid><addsrcrecordid>eNp9kMFO3DAQhq0K1F1oX6AH5COHhrUdx06OaEVbpJV6AfVoTZJJ10viLLYDymv1QfpMmC4gTj3NSPPNr5mPkC-cXXDG9CpIpgTLmBAZ44XKs_kDWXItZKZYUR296xfkJIQdY6IohPxIFrnSvCiFWJL2l4urv3-yBiI66-ge4vYRZmrd1tY2jj58pfXokA4YoR57GwYKrqUPEJqpB0-3CH3cJp7e2dbhTKMHF_Y9uPgcZtHF8Ikcd9AH_PxST8ntt6ub9Y9s8_P79fpykzW51DGTVaehFJ1U6bSirEApXVSCl5USEspGNC22WrJaQg1FqzUyxbsaBdZcqZzlp-T8kLv34_2EIZrBhgb7dAyOUzBCa87KstR5QsUBbfwYgsfO7L0dwM-GM_Ns1xzsmmTX_LNr5rR09pI_1QO2byuvOhOQH4CQRu43erMbJ-_Sz_-LfQLoy4dz</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2771088873</pqid></control><display><type>article</type><title>Wnt/β-catenin pathway inhibitors, bone metabolism and vascular health in kidney transplant patients</title><source>Springer Nature - Complete Springer Journals</source><creator>Wang, Yue-Pei ; Sidibé, Aboubacar ; Fortier, Catherine ; Desjardins, Marie-Pier ; Ung, Roth-Visal ; Kremer, Richard ; Agharazii, Mohsen ; Mac-Way, Fabrice</creator><creatorcontrib>Wang, Yue-Pei ; Sidibé, Aboubacar ; Fortier, Catherine ; Desjardins, Marie-Pier ; Ung, Roth-Visal ; Kremer, Richard ; Agharazii, Mohsen ; Mac-Way, Fabrice</creatorcontrib><description>Background and objectives
Sclerostin, dickkopf-related protein 1 (DKK1), fibroblast growth factor-23 (FGF23) and α-klotho have been shown to play an important role in bone and vascular disease of chronic kidney disease. We aimed to evaluate the evolution of these bone markers in newly kidney transplanted patients, and whether they are associated with bone metabolism and vascular stiffness.
Design, setting, participants and measurements
This is a longitudinal single-center observational cohort study. Circulating levels of Wnt/β-catenin pathway inhibitors (sclerostin, DKK1, FGF23 and α-klotho), arterial stiffness (carotid-femoral pulse-wave velocity (PWV), carotid-radial PWV, PWV ratio, augmented index) and bone parameters were assessed before (M0), and at 3 (M3) and 6 months (M6) after transplantation. Generalized estimating equations were conducted for comparative analyses between the three time points. We used a marginal structural model for repeated measures for the impact of changes in bone markers on the evolution of arterial stiffness. Multivariate linear regression analyses were performed for the associations between Wnt/β-catenin pathway inhibitors and mineral metabolism parameters.
Results
We included 79 patients (70% male; median age of 53 (44–60) years old). The levels of sclerostin (2.06 ± 1.18 ng/mL at M0 to 0.88 ± 0.29 ng/mL at M6,
p
≤ 0.001), DKK1 (364.0 ± 266.7 pg/mL at M0 to 246.7 ± 149.1 pg/mL at M6,
p
≤ 0.001), FGF23 (5595 ± 9603 RU/mL at M0 to 137 ± 215 RU/mL at M6,
p
≤ 0.001) and α-klotho (457.6 ± 148.6 pg/mL at M0 to 109.8 ± 120.7 pg/mL at M6,
p
< 0.05) decreased significantly after kidney transplant. Sclerostin and FGF23 were positively associated with carotid-femoral (standardized
β
= 0.432,
p
= 0.037 and standardized
β
= 0.592,
p
= 0.005) and carotid-radial PWV (standardized
β
= 0.259,
p
= 0.029 and standardized
β
= 0.242,
p
= 0.006) throughout the 6 months of follow-up. The nature of the associations between bone markers and bone metabolism parameters varies after kidney transplant.
Conclusions
The circulating levels of Wnt/β-catenin pathway inhibitors and α-klotho significantly decrease after kidney transplantation, while sclerostin and FGF23 levels might be associated with improvement of vascular stiffness and blood pressure.
Graphical abstract</description><identifier>ISSN: 1724-6059</identifier><identifier>EISSN: 1724-6059</identifier><identifier>DOI: 10.1007/s40620-022-01563-y</identifier><identifier>PMID: 36715822</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Medicine ; Medicine & Public Health ; Nephrology ; original Article ; Urology</subject><ispartof>Journal of nephrology, 2023-05, Vol.36 (4), p.969-978</ispartof><rights>The Author(s) under exclusive licence to Italian Society of Nephrology 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2023. The Author(s) under exclusive licence to Italian Society of Nephrology.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c347t-49f7a82f46822589a667592189624a8c2cded740b4aba5d77e061fbe2eb166303</citedby><cites>FETCH-LOGICAL-c347t-49f7a82f46822589a667592189624a8c2cded740b4aba5d77e061fbe2eb166303</cites><orcidid>0000-0002-6475-5336 ; 0000-0002-5596-622X ; 0000-0002-7053-2139 ; 0000-0002-6879-9344 ; 0000-0002-0368-2313 ; 0000-0001-8242-6635 ; 0000-0002-7628-5757 ; 0000-0003-0919-9661</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s40620-022-01563-y$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s40620-022-01563-y$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,778,782,27911,27912,41475,42544,51306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36715822$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Yue-Pei</creatorcontrib><creatorcontrib>Sidibé, Aboubacar</creatorcontrib><creatorcontrib>Fortier, Catherine</creatorcontrib><creatorcontrib>Desjardins, Marie-Pier</creatorcontrib><creatorcontrib>Ung, Roth-Visal</creatorcontrib><creatorcontrib>Kremer, Richard</creatorcontrib><creatorcontrib>Agharazii, Mohsen</creatorcontrib><creatorcontrib>Mac-Way, Fabrice</creatorcontrib><title>Wnt/β-catenin pathway inhibitors, bone metabolism and vascular health in kidney transplant patients</title><title>Journal of nephrology</title><addtitle>J Nephrol</addtitle><addtitle>J Nephrol</addtitle><description>Background and objectives
Sclerostin, dickkopf-related protein 1 (DKK1), fibroblast growth factor-23 (FGF23) and α-klotho have been shown to play an important role in bone and vascular disease of chronic kidney disease. We aimed to evaluate the evolution of these bone markers in newly kidney transplanted patients, and whether they are associated with bone metabolism and vascular stiffness.
Design, setting, participants and measurements
This is a longitudinal single-center observational cohort study. Circulating levels of Wnt/β-catenin pathway inhibitors (sclerostin, DKK1, FGF23 and α-klotho), arterial stiffness (carotid-femoral pulse-wave velocity (PWV), carotid-radial PWV, PWV ratio, augmented index) and bone parameters were assessed before (M0), and at 3 (M3) and 6 months (M6) after transplantation. Generalized estimating equations were conducted for comparative analyses between the three time points. We used a marginal structural model for repeated measures for the impact of changes in bone markers on the evolution of arterial stiffness. Multivariate linear regression analyses were performed for the associations between Wnt/β-catenin pathway inhibitors and mineral metabolism parameters.
Results
We included 79 patients (70% male; median age of 53 (44–60) years old). The levels of sclerostin (2.06 ± 1.18 ng/mL at M0 to 0.88 ± 0.29 ng/mL at M6,
p
≤ 0.001), DKK1 (364.0 ± 266.7 pg/mL at M0 to 246.7 ± 149.1 pg/mL at M6,
p
≤ 0.001), FGF23 (5595 ± 9603 RU/mL at M0 to 137 ± 215 RU/mL at M6,
p
≤ 0.001) and α-klotho (457.6 ± 148.6 pg/mL at M0 to 109.8 ± 120.7 pg/mL at M6,
p
< 0.05) decreased significantly after kidney transplant. Sclerostin and FGF23 were positively associated with carotid-femoral (standardized
β
= 0.432,
p
= 0.037 and standardized
β
= 0.592,
p
= 0.005) and carotid-radial PWV (standardized
β
= 0.259,
p
= 0.029 and standardized
β
= 0.242,
p
= 0.006) throughout the 6 months of follow-up. The nature of the associations between bone markers and bone metabolism parameters varies after kidney transplant.
Conclusions
The circulating levels of Wnt/β-catenin pathway inhibitors and α-klotho significantly decrease after kidney transplantation, while sclerostin and FGF23 levels might be associated with improvement of vascular stiffness and blood pressure.
Graphical abstract</description><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Nephrology</subject><subject>original Article</subject><subject>Urology</subject><issn>1724-6059</issn><issn>1724-6059</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kMFO3DAQhq0K1F1oX6AH5COHhrUdx06OaEVbpJV6AfVoTZJJ10viLLYDymv1QfpMmC4gTj3NSPPNr5mPkC-cXXDG9CpIpgTLmBAZ44XKs_kDWXItZKZYUR296xfkJIQdY6IohPxIFrnSvCiFWJL2l4urv3-yBiI66-ge4vYRZmrd1tY2jj58pfXokA4YoR57GwYKrqUPEJqpB0-3CH3cJp7e2dbhTKMHF_Y9uPgcZtHF8Ikcd9AH_PxST8ntt6ub9Y9s8_P79fpykzW51DGTVaehFJ1U6bSirEApXVSCl5USEspGNC22WrJaQg1FqzUyxbsaBdZcqZzlp-T8kLv34_2EIZrBhgb7dAyOUzBCa87KstR5QsUBbfwYgsfO7L0dwM-GM_Ns1xzsmmTX_LNr5rR09pI_1QO2byuvOhOQH4CQRu43erMbJ-_Sz_-LfQLoy4dz</recordid><startdate>20230501</startdate><enddate>20230501</enddate><creator>Wang, Yue-Pei</creator><creator>Sidibé, Aboubacar</creator><creator>Fortier, Catherine</creator><creator>Desjardins, Marie-Pier</creator><creator>Ung, Roth-Visal</creator><creator>Kremer, Richard</creator><creator>Agharazii, Mohsen</creator><creator>Mac-Way, Fabrice</creator><general>Springer International Publishing</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6475-5336</orcidid><orcidid>https://orcid.org/0000-0002-5596-622X</orcidid><orcidid>https://orcid.org/0000-0002-7053-2139</orcidid><orcidid>https://orcid.org/0000-0002-6879-9344</orcidid><orcidid>https://orcid.org/0000-0002-0368-2313</orcidid><orcidid>https://orcid.org/0000-0001-8242-6635</orcidid><orcidid>https://orcid.org/0000-0002-7628-5757</orcidid><orcidid>https://orcid.org/0000-0003-0919-9661</orcidid></search><sort><creationdate>20230501</creationdate><title>Wnt/β-catenin pathway inhibitors, bone metabolism and vascular health in kidney transplant patients</title><author>Wang, Yue-Pei ; Sidibé, Aboubacar ; Fortier, Catherine ; Desjardins, Marie-Pier ; Ung, Roth-Visal ; Kremer, Richard ; Agharazii, Mohsen ; Mac-Way, Fabrice</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c347t-49f7a82f46822589a667592189624a8c2cded740b4aba5d77e061fbe2eb166303</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Nephrology</topic><topic>original Article</topic><topic>Urology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Yue-Pei</creatorcontrib><creatorcontrib>Sidibé, Aboubacar</creatorcontrib><creatorcontrib>Fortier, Catherine</creatorcontrib><creatorcontrib>Desjardins, Marie-Pier</creatorcontrib><creatorcontrib>Ung, Roth-Visal</creatorcontrib><creatorcontrib>Kremer, Richard</creatorcontrib><creatorcontrib>Agharazii, Mohsen</creatorcontrib><creatorcontrib>Mac-Way, Fabrice</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of nephrology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Yue-Pei</au><au>Sidibé, Aboubacar</au><au>Fortier, Catherine</au><au>Desjardins, Marie-Pier</au><au>Ung, Roth-Visal</au><au>Kremer, Richard</au><au>Agharazii, Mohsen</au><au>Mac-Way, Fabrice</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Wnt/β-catenin pathway inhibitors, bone metabolism and vascular health in kidney transplant patients</atitle><jtitle>Journal of nephrology</jtitle><stitle>J Nephrol</stitle><addtitle>J Nephrol</addtitle><date>2023-05-01</date><risdate>2023</risdate><volume>36</volume><issue>4</issue><spage>969</spage><epage>978</epage><pages>969-978</pages><issn>1724-6059</issn><eissn>1724-6059</eissn><abstract>Background and objectives
Sclerostin, dickkopf-related protein 1 (DKK1), fibroblast growth factor-23 (FGF23) and α-klotho have been shown to play an important role in bone and vascular disease of chronic kidney disease. We aimed to evaluate the evolution of these bone markers in newly kidney transplanted patients, and whether they are associated with bone metabolism and vascular stiffness.
Design, setting, participants and measurements
This is a longitudinal single-center observational cohort study. Circulating levels of Wnt/β-catenin pathway inhibitors (sclerostin, DKK1, FGF23 and α-klotho), arterial stiffness (carotid-femoral pulse-wave velocity (PWV), carotid-radial PWV, PWV ratio, augmented index) and bone parameters were assessed before (M0), and at 3 (M3) and 6 months (M6) after transplantation. Generalized estimating equations were conducted for comparative analyses between the three time points. We used a marginal structural model for repeated measures for the impact of changes in bone markers on the evolution of arterial stiffness. Multivariate linear regression analyses were performed for the associations between Wnt/β-catenin pathway inhibitors and mineral metabolism parameters.
Results
We included 79 patients (70% male; median age of 53 (44–60) years old). The levels of sclerostin (2.06 ± 1.18 ng/mL at M0 to 0.88 ± 0.29 ng/mL at M6,
p
≤ 0.001), DKK1 (364.0 ± 266.7 pg/mL at M0 to 246.7 ± 149.1 pg/mL at M6,
p
≤ 0.001), FGF23 (5595 ± 9603 RU/mL at M0 to 137 ± 215 RU/mL at M6,
p
≤ 0.001) and α-klotho (457.6 ± 148.6 pg/mL at M0 to 109.8 ± 120.7 pg/mL at M6,
p
< 0.05) decreased significantly after kidney transplant. Sclerostin and FGF23 were positively associated with carotid-femoral (standardized
β
= 0.432,
p
= 0.037 and standardized
β
= 0.592,
p
= 0.005) and carotid-radial PWV (standardized
β
= 0.259,
p
= 0.029 and standardized
β
= 0.242,
p
= 0.006) throughout the 6 months of follow-up. The nature of the associations between bone markers and bone metabolism parameters varies after kidney transplant.
Conclusions
The circulating levels of Wnt/β-catenin pathway inhibitors and α-klotho significantly decrease after kidney transplantation, while sclerostin and FGF23 levels might be associated with improvement of vascular stiffness and blood pressure.
Graphical abstract</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>36715822</pmid><doi>10.1007/s40620-022-01563-y</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-6475-5336</orcidid><orcidid>https://orcid.org/0000-0002-5596-622X</orcidid><orcidid>https://orcid.org/0000-0002-7053-2139</orcidid><orcidid>https://orcid.org/0000-0002-6879-9344</orcidid><orcidid>https://orcid.org/0000-0002-0368-2313</orcidid><orcidid>https://orcid.org/0000-0001-8242-6635</orcidid><orcidid>https://orcid.org/0000-0002-7628-5757</orcidid><orcidid>https://orcid.org/0000-0003-0919-9661</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1724-6059 |
| ispartof | Journal of nephrology, 2023-05, Vol.36 (4), p.969-978 |
| issn | 1724-6059 1724-6059 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2771088873 |
| source | Springer Nature - Complete Springer Journals |
| subjects | Medicine Medicine & Public Health Nephrology original Article Urology |
| title | Wnt/β-catenin pathway inhibitors, bone metabolism and vascular health in kidney transplant patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T01%3A38%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Wnt/%CE%B2-catenin%20pathway%20inhibitors,%20bone%20metabolism%20and%20vascular%20health%20in%20kidney%20transplant%20patients&rft.jtitle=Journal%20of%20nephrology&rft.au=Wang,%20Yue-Pei&rft.date=2023-05-01&rft.volume=36&rft.issue=4&rft.spage=969&rft.epage=978&rft.pages=969-978&rft.issn=1724-6059&rft.eissn=1724-6059&rft_id=info:doi/10.1007/s40620-022-01563-y&rft_dat=%3Cproquest_cross%3E2771088873%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2771088873&rft_id=info:pmid/36715822&rfr_iscdi=true |